An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 936-943

  Jilani, Iman ^a   Kantarjian, Hagop ^b   Faraji, Homan ^a   Gorre, Mercedes ^a   Cortes, Jorge ^b   Ottmann, Oliver ^c   Bhalla, Kapil ^d   O'Brien, Susan ^b   Giles, Francis ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BCR ABL; Beads; CML; Fusion protein; Imatinib; MDR; Phosphorylation

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DETECTION; ARTICLE; CHRONIC MYELOID LEUKEMIA; FLOW CYTOMETRY; GENE TRANSLOCATION; HUMAN; IMMUNOASSAY; PATIENT MONITORING; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOASSAY; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; PHOSPHORYLATION; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 40849147403     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.023     Document Type: Article

References (16)

1. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al., International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
2. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al., IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
3. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
4. Hochhaus A., and La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18 (2004) 1321-1331
5. Martinelli G., Soverini S., Rosti G., Cilloni D., and Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 90 (2005) 534-541
6. O'Hare T., Walters D.K., Deininger M.W., and Druker B.J. AMN107: tightening the grip of imatinib. Cancer Cell 7 (2005) 117-119
7. Kantarjian H.M., Talpaz M., Cortes J., O'Brien S., Faderl S., Thomas D., et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 9 (2003) 160-166
8. Müller M.C., Gattermann N., Lahaye T., Deininger M.W., Berndt A., Fruehauf S., et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 17 (2003) 2392-2400
9. Brasher B.B., and Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275 (2000) 35631-35637
10. Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C., et al. Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci USA 100 (2003) 443-448
11. Marley S.B., Lewis J.L., Schneider H., Rudd C.E., and Gordon M.Y. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. Br J Haematol 125 (2004) 500-511
12. Albitar M., Do K.A., Johnson M.M., Giles F.J., Jilani I., O'Brien S., et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 101 (2004) 999-1008
13. Rogers A., Joe Y., Manshouri T., Dey A., Jilani I., Giles F., et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 103 (2004) 2799-2801
14. Cortes J., Giles F., O'Brien S., Thomas D., Albitar M., Rios M.B., et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97 (2003) 2760-2766
15. Ma W., Tseng R., Gorre M., Jilani I., Keating M., Kantarjian H., et al. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 92 (2007) 170-175
16. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22 (2004) 935-942